The vaccine uses HLA-DR on antigen-presenting cells to present peptides and prime neoantigen-specific T cells; the resulting CD8+ CTLs kill tumor cells presenting the neoantigen on MHC I via perforin/granzyme, not by targeting HLA-DR-expressing cells.